Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong

2009 ◽  
Vol 9 (2) ◽  
pp. 221-228 ◽  
Author(s):  
Wai Tong Ng ◽  
Cheuk Wai Choi ◽  
Michael C. H. Lee ◽  
Lai Yau Law ◽  
Tsz Kok Yau ◽  
...  
2020 ◽  
pp. bjophthalmol-2020-317373
Author(s):  
Anindyt Nagar ◽  
Sam Myers ◽  
Diana Kozareva ◽  
Mark Simcoe ◽  
Christopher Hammond

Background/aimsCascade screening has been used successfully in relatives of patients with inherited cancers and other genetic diseases to identify presymptomatic disease. This study was designed to examine if this approach would be successful in a high-risk group: first-degree relatives (FDR) of African-Caribbean glaucoma patients resident in London.MethodsAfrican-Caribbean patients (probands) with glaucoma from an inner London hospital setting in a deprived area were asked to disseminate personalised information to their FDR over the age of 30 and to arrange a free hospital-based screening. Data collected, including optical coherence tomography imaging, were reviewed by a glaucoma specialist and if glaucoma was diagnosed or suspected, local specialist referral via family doctor was made.Results203 probands were recruited from glaucoma clinics. 248 suitable FDR were identified as potentially eligible to attend screening. 57 (23%) FDR made contact with the research team of whom 18 (7%) attended a subsequent screening visit. No patients were diagnosed with glaucoma; one participant was diagnosed as glaucoma suspect. Reasons for poor uptake included reluctance by probands to involve their family members, and retirees spending significant time abroad.ConclusionCascade screening of FDR of African-Caribbean glaucoma patients in inner city London was unsuccessful. Research confidentiality guidance prohibiting research teams directly contacting family members was a barrier. Greater community engagement, community-based screening and permission to contact FDR directly might have improved uptake.


2000 ◽  
Vol 86 (9) ◽  
pp. K40-K43 ◽  
Author(s):  
Pedro Brugada ◽  
Ramon Brugada ◽  
Josep Brugada

2011 ◽  
Vol 40 (6) ◽  
pp. 246-251 ◽  
Author(s):  
June E. Swartz ◽  
Erica Perry ◽  
Sally Joy ◽  
Richard D. Swartz

2006 ◽  
Vol 8 (12) ◽  
pp. 760-770 ◽  
Author(s):  
June A Peters ◽  
Susan T Vadaparampil ◽  
Joan Kramer ◽  
Richard P Moser ◽  
Lori Jo Peterson Court ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4385
Author(s):  
Kari Hemminki ◽  
Kristina Sundquist ◽  
Jan Sundquist ◽  
Asta Försti ◽  
Akseli Hemminki ◽  
...  

Background: Familial cancer can be defined through the occurrence of the same cancer in two or more family members. We describe a nationwide landscape of familial cancer, including its frequency and the risk that it conveys, by using the largest family database in the world with complete family structures and medically confirmed cancers. Patients/methods: We employed standardized incidence ratios (SIRs) to estimate familial risks for concordant cancer among first-degree relatives using the Swedish Cancer Registry from years 1958 through 2016. Results: Cancer risks in a 20–84 year old population conferred by affected parents or siblings were about two-fold compared to the risk for individuals with unaffected relatives. For small intestinal, testicular, thyroid and bone cancers and Hodgkin disease, risks were higher, five-to-eight-fold. Novel familial associations included adult bone, lip, pharyngeal, and connective tissue cancers. Familial cancers were found in 13.2% of families with cancer; for prostate cancer, the proportion was 26.4%. High-risk families accounted for 6.6% of all cancer families. Discussion/Conclusion: High-risk family history should be exceedingly considered for management, including targeted genetic testing. For the major proportion of familial clustering, where genetic testing may not be feasible, medical and behavioral intervention should be indicated for the patient and their family members, including screening recommendations and avoidance of carcinogenic exposure.


2017 ◽  
Vol 74 (3) ◽  
pp. 293 ◽  
Author(s):  
Zongqi Xia ◽  
Sonya U. Steele ◽  
Anshika Bakshi ◽  
Sarah R. Clarkson ◽  
Charles C. White ◽  
...  

2007 ◽  
Vol 17 (3) ◽  
pp. 180-182 ◽  
Author(s):  
Jerome F. O'Hara ◽  
Katrina Bramstedt ◽  
Stewart Flechner ◽  
David Goldfarb

Evaulating patients for living kidney donor transplantation involving a recipient with significant medical issues can create an ethical debate about whether to proceed with surgery. Donors must be informed of the surgical risk to proceed with donating a kidney and their decision must be a voluntary one. A detailed informed consent should be obtained from high-risk living kidney donor transplant recipients as well as donors and family members after the high perioperative risk potential has been explained to them. In addition, family members need to be informed of and acknowledge that a living kidney donor transplant recipient with pretransplant extrarenal morbidity has a higher risk of a serious adverse outcome event such as graft failure or recipient death. We review 2 cases involving living kidney donor transplant recipients with significant comorbidity and discuss ethical considerations, donor risk, and the need for an extended informed consent.


Sign in / Sign up

Export Citation Format

Share Document